

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 March 2002 (21.03.2002)

PCT

(10) International Publication Number
WO 02/22158 A1

- (51) International Patent Classification⁷: **A61K 38/13**, 9/107, 9/48
- (21) International Application Number: **PCT/IN00/00091**
- (22) International Filing Date:
18 September 2000 (18.09.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (71) Applicant (for all designated States except US): **RPG LIFE SCIENCES LIMITED** [IN/IN]; Ceat Mahal, 463, Dr. Annie Besant Road, Worli, Mumbai 400 025, Maharashtra (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CHAKRAVORTY**, Saibal [IN/IN]; RPG Life Sciences Limited, Ceat Mahal, 463, Dr. Annie Besant Road, Worli, Mumbai 400 025, Maharashtra (IN). **BHARTI**, Prasad [IN/IN]; RPG Life Sciences Limited, Ceat Mahal, 463, Dr. Annie Besant Road, Worli, Mumbai 400 025, Maharashtra (IN).
- (74) Agent: **MEHTA, Ramesh, Kumar**; Remfry & Sagar, Attorneys-at-Law, Remfry House, 8, Nangal Raya Business Centre, New Delhi 110 046 (IN).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— with amended claims and statement
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 02/22158 A1

(54) Title: **SELFEMULSIFIABLE FORMULATION HAVING ENHANCED BIOABSORPTION AND IMMUNOSUPPRESSION ACTIVITIES**

(57) Abstract: A selfemulsifiable formulation comprising of lipophilic system consisting of medium chain triglyceride of caprylic acid and capric acid, and of labrasol, wherein labrasol also serves as surfactant, which is combined with other selected surfactants, like cremophore RH 40 and/or polysorbate 80 is disclosed, wherein said formulation also comprises of immunosuppression agent essentially cyclosporine, hydrophilic agent preferably ethanol, antioxidant preferably alpha-tocopherol and preservative preferably benzyl alcohol, and said formulation is prepared by dissolving immunosuppression agent in hydrophilic agent followed by entrapping with lipophilic agent and subsequent treatment with surfactants, preservative and antioxidant, and is filled in soft-gelatine shell capable of rupturing in less than 10 minutes to deliver said formulation in upper part of gastrointestinal tract, wherein it forms thermodynamically stable oil in water microemulsions *in situ* to have enhanced bioavailability and bioabsorption of immunosuppression agent, which can show its enhanced immunosuppression activities thereby.

TITLE OF INVENTION

Selfemulsifiable Formulation having enhanced Bioabsorption and Immunosuppression Activities

Technical Field of Invention

5 The present invention relates to a formulation, particularly to a selfemulsifiable formulation for oral administration having enhanced bioabsorption and immunosuppression activities, more particularly it relates to a selfemulsifiable formulation for early delivery of drug, even more particularly it relates to a selfemulsifiable formulation, which will form thermodynamically stable oil in water emulsion preferably in
10 upper part of gastrointestinal tract and facilitate the early delivery of drug, particularly of the immunosuppression agent, still more particularly it relates to a selfemulsifiable formulation not only having the improved bioavailability and bioabsorption but also has improved capability to release the drug in reduced time with reduced toxicity and variability that is inter and intra patient bioabsorption variability. The present invention
15 particularly relates to a selfemulsifiable formulation, which facilitates increased solubility, transport rate, bioavailability and bioabsorption of an agent having immunosuppression activity.

Background Art of Invention

 The immunosuppression activity of a drug acting as an immunosuppression agent
20 is achieved by inhibiting the growth and differentiation of T-cells. Such immunosuppression agents also have other pharmacological activities like anti-inflammatory and/or antiparasitic, in particular antiprotozoal, like antimalarial activities. The commonly used immunosuppression agents include cyclosporine. There are many cyclosporines known in the art, like cyclosporine A, cyclosporine B, cyclosporine C,
25 cyclosporine D, cyclosporine E etc. The cyclosporine A is preferably used in the clinical field due to its proven pharmacological activity and clinical indication and effectiveness.

 This immunosuppression agent, that is, cyclosporine A has been found useful in various other areas, like in autoimmune diseases, inflammatory conditions, particularly in inflammatory conditions with an aetiology including an autoimmune component like
30 arthritis.

 Further, this immunosuppression agent is applicable in rheumatoid arthritis, arthritis chronica, and progredientic and arthritis deformana. Further, this immunosuppression agent is also applicable in rheumatic diseases.

The immunosuppression therapy using this immunosuppression agent has been proposed or applied in autoimmune hematological disorder, like hemolytic anemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopaenia, systemic lupus erythematosus, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic spure, autoimmune inflammatory bowel disease including ulcerative colitis and crohn's disease, endocrine ophthalmopathy, Graves disease, sarcoidosis, multiple sclerosis, primary billiary cirrhosis, juvenile diabetes, like diabetes mellitus Type I, anterior and posterior uveitis, and keratoconjunctivities sicca an vernal keratoconjunctivities, intestinal lung fibrosis, psoriatic arthritis and glomerulonephritis - with or without nephrotic syndrome, like idiopathic nephrotic syndrome or minimal change nephropathy.

Therefore, this immunosuppression agent is widely acceptable immunosuppression agent. This agent is made available in the form of pharmaceutical formulation. The clinical acceptance of such formulations comprising of this immunosuppression agent has suffered due to low solubility and low transport rate and delayed bioavailability and bioabsorption of the immunosuppression agent.

Therefore, in recent past the research has been directed to improve its solubility and transport rate. In addition efforts have been on to improve its early bioavailability, particularly in the upper part of the gastrointestinal tract and bioabsorption.

Various formulations, comprising this immunosuppression agent as one of the essential ingredients, have been developed and made available. Although there are many formulations to form microemulsions, but many of them do not have satisfactorily acceptable bioavailability and bioabsorption. The formation of microemulsions of the clinically acceptable particle size that is of less than 200 nm, particularly of less than 100 nm, is one of the desired requirements for the formulation to be clinically acceptable. Therefore, the efforts are still on to develop new formulations, particularly the formulations which will have better bioavailability, particularly in the upper part of the gastrointestinal tract and better bioabsorption and at the same time will have better solubility and reduced variability, that is inter and intra patient bioabsorption variability, and form the microemulsions of the clinically acceptable particle size.

The another parameter controlling the applicability of formulations of the immunosuppression agent is its manner of administration. The formulation comprising of the immunosuppression agent, particularly of this immunosuppression agent is generally

administered after filling it in a soft or hard shell, known as capsule, or in the form of solution for oral administration. The solution form of formulation of the immunosuppression agent is taken after dilution with flavored milk or fruit juice. The mixing with milk or the juice forms the emulsion, particularly microemulsions of varying particle sizes, generally varying above 100 nm, preferably varying above 150 nm. The preferred form of administration of the formulation of this immunosuppression agent is after filling the formulation in a shell, which may be soft or hard shell.

The major problem arises, when the immunosuppression agent or its formulation is administered after filling in a hard or soft-shell. It has been generally observed that, the availability of the immunosuppression agent will depend upon the rupture time of the shell.

The known formulations of the immunosuppression agent, which are made available in the shell, have rupture time of shell varying from 12 minutes to 15 minutes or above. The problem arises due to this longer rupture time, which delays the availability of the immunosuppression agent, which in-turn effects its bioabsorption. The desired rupture time of the shell in order to make the availability of the immunosuppression agent at an early time, preferably in the upper part of the gastrointestinal tract is less than 12 minutes, preferably less than 10 minutes.

Need of Invention

Therefore, there is a need to have a formulation, particularly a selfemulsifiable formulation for oral administration, which can overcome all or some of the disadvantages and limitations of the prior art, as described herein above and more particularly of a selfemulsifiable formulation, which facilitates increased solubility, transport rate, bioavailability and bioabsorption of the immunosuppression agent.

Objects of Invention

This is the main object of the present invention to make a complete disclosure of a formulation, particularly of a selfemulsifiable formulation for oral administration, which can overcome all or some of the disadvantages and limitations of the prior art, as described herein above and more particularly of a selfemulsifiable formulation, which can facilitate the increased solubility, transport rate, bioavailability and bioabsorption of the immunosuppression agent.

Another object of this invention is to propose for a selfemulsifiable formulation capable of making early bioavailability of the immunosuppression agent, particularly in the upper part of the gastrointestinal tract.

Still another object of this invention is to propose a selfemulsifiable formulation,
5 which can satisfactorily meet the clinical requirements.

Still further an object of the present invention is to disclose a selfemulsifiable formulation, which can form microemulsions of particle size less than 200 nm, preferably less than 100 nm.

Yet another object of this invention is to propose a selfemulsifiable formulation,
10 which can administered orally after filling in a soft or hard shell, or in the form of solution.

This is further an object of this invention to disclose a selfemulsifiable formulation, which can form microemulsions of particle size less than 200 nm, preferably less than 100 nm and a clear solution when administered orally in the form of microemulsions mixed with fruit juice, milk or any aqueous medium.

15 This is still an object of this invention to disclose a selfemulsifiable formulation, which can form microemulsions of particle size less than 200 nm, preferably less than 100 nm when administered orally after filling in a soft or hard shell.

This is yet an object of this invention to disclose a selfemulsifiable formulation, which on administration in a shell, particularly in a soft shell is made available at an early
20 time, preferably in the upper part of the gastrointestinal tract in less than 12 minutes, more preferably in less than 10 minutes, by rupturing the shell in desired time of less than 12 minutes.

This is still an object of this invention to disclose a selfemulsifiable formulation, which has better solubility and reduced variability, that is inter and intra patient
25 bioabsorption variability.

Still another an object of this invention is to disclose a selfemulsifiable formulation, which can be stored in the tropical countries for a longer time and can forms thermodynamically stable oil in water microemulsions *in-situ*, which are stable for more than 24 hrs.

30 Yet another an object of this invention is to disclose a selfemulsifiable formulation and the method of preparation thereof.

Further objects, advantages and preferred embodiments of the present invention will be more apparent from the following description when read in conjunction with the

accompanying drawings, which are not intended to limit the scope of the present invention.

Description of the Figures

Figure 1 shows the phase diagram of the selfemulsifiable formulation in accordance to the preferred embodiments of the present invention.

Figure 2 shows the phase diagram representing the relative concentration of oil phase, water phase and mixture of surfactants of the selfemulsifiable formulation in accordance to the preferred embodiments of the present invention.

Figure 3 shows the comparative dissolution profile of experiments XIII, XIV and XV of the selfemulsifiable formulation in accordance to the preferred embodiments of the present invention and of Sandimmun Neoral, which is taken as standard.

Figure 4 shows the percent amount of normalized particle size in experiment XV, the best preferred experiment of the selfemulsifiable formulation in accordance to the preferred embodiments of the present invention.

Figure 5 shows the mean plasma concentration of the immunosuppression agent after administration of formulation, after filled in soft-shell, of experiment XV, the best preferred experiment of the selfemulsifiable formulation in accordance to the preferred embodiments of the present invention.

Figure 6 shows the compositions of formulations prepared in accordance to the preferred method of the present invention.

Brief Description of Invention

Accordingly this invention provides a complete disclosure of a formulation, particularly of a selfemulsifiable formulation for oral administration, which has enhanced bioabsorption and immunosuppression activities, more particularly of a selfemulsifiable formulation for early delivery of drug, even more particularly of a selfemulsifiable formulation, which will form thermodynamically stable oil in water emulsion preferably in upper part of gastrointestinal tract and facilitate the early delivery of drug, particularly of the immunosuppression agent, still more particularly of a selfemulsifiable formulation not only having the improved bioavailability and bioabsorption but also the improved capability to release the drug in reduced time with reduced toxicity and variability, that is inter and intra patient bioabsorption variability.

In accordance to the present invention a selfemulsifiable formulation is disclosed, which facilitates the increased solubility, transport rate, bioavailability and bioabsorption

of an agent, particularly of an immunosuppression agent, wherein said formulation essentially comprises of immunosuppression agent, hydrophilic agent, lipophilic agent, one or more of surfactants, antioxidant and preservative. In accordance to one of the preferred embodiments of the present invention the formulation is made available in a shell; preferably soft shell, wherein the said shell essentially comprises of gelatin, glycerin, water, one or more of preservatives and one or more of colorants.

The formulation of the present invention can be prepared by any known method. In accordance to the preferred embodiment of the present invention the preferred method, for preparation the presently disclosed selfemulsifiable formulation comprises of dissolution of immunosuppression agent in hydrophilic agent followed by entrapping of solubilised immunosuppression agent with lipophilic agent, which in-turn is followed by treatment of oil entrapped solubilised form of drug with one or more of surfactants and the resulted solubilised drug entrapped with oil and one or more of surfactants is treated with preservative and antioxidant.

Detailed Description and Preferred Embodiments of Invention

In accordance with this invention a selfemulsifiable formulation for oral administration, as described herein above, is disclosed, wherein said formulation essentially comprises of immunosuppression agent, hydrophilic agent, lipophilic agent, one or more of surfactants, antioxidant and preservative, wherein immunosuppression agent is preferably lactam macrolide having immunosuppression activity; hydrophilic agent is selected from a group consisting of pharmaceutically acceptable C₁₋₅ alkyl, tetrahydrofuryl diether, tetrahydrofuryl partial ether, low molecular weight monooxy-alkane-diol, low molecular weight polyoxy-alkane-diol, 1,2-propyleneglycol, ethanol; lipophilic agent is selected from a group consisting of medium chain monoglycerides, medium chain diglycerides, mixed esters of saturated fatty acids, like caprylic and/or capric acids, medium chain triglycerides of caprylic and/or capric acids; one or more of surfactant is selected from a group consisting of hydrogenated vegetable oils, polyoxyethylene sorbitan fatty acids, transesterified caprylic and/or capric glycerides; antioxidant is selected from a group consisting of alpha-tocopherol, ascorbyl palmitate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gallate; preservative is selected from a group consisting of ethanol, benzyl alcohol.

In accordance to the most preferred embodiment of the present invention, it has been surprisingly found that to have particular stable microemulsions of clinically

acceptable particle size with enhanced bioavailability and reduced variability in inter and intra-patient dose response, are obtained by using novel lipophilic agent of the present invention. The most preferred lipophilic agent of the present invention, which may also be referred to, as drug or immunosuppression agent carrier is medium chain triglyceride of caprylic acid and capric acid, named to as labrafac lipophile. In accordance to the preferred embodiment of the present invention the medium chain triglyceride of caprylic acid and capric acid, which is used as lipophilic agent in the presently disclosed formulation is obtained by any known method, like by esterification of glycerol by caprylic acid and capric acid at high temperature. The medium chain triglyceride of caprylic acid and capric acid, which is selected as lipophilic agent has specific gravity of about 0.93 to 0.96, refractive index of about 1.44 to 1.452, acid value less than about 0.2, saponification value of about 310 to 360 and iodine value less than about 1 and water content less than about 0.5.

In accordance to one of the preferred embodiments of the present invention immunosuppression agent is cyclosporine, particularly cyclosporine A having immunosuppression activity; hydrophilic agent is additionally selected from a group consisting of pharmaceutically acceptable lower (C_{1-4}) alkanols, like ethanol; alkylene glycol monoalkyl ethers, like diethylene glycol monoethyl ethers, transcitol, glycofural (known as tetrahydrofuryl) alcohol polyethylene glycol ether. The preferred hydrophilic agent is lower alkanol, preferably ethanol.

The preferred lipophilic agent is medium chain triglyceride of caprylic acid and capric acid.

The surfactant, one or more, is/are additionally selected from a group consisting of saturated polyglycolysed C_8 to C_{10} glycerides, like transesterified caprylic and/or capric glycerides, particularly PEG-8 caprylic and/or capric acid glyceride exhibiting specific gravity of about 0.930 to 0.960, refractive index of about 1.44 to 1.452, acid value less than about 0.2, saponification value of about 85 to 105, peroxide value less than about 6.0. free glycerol content less than about 5.0%, ethylene oxide content of about 1.0 ppm, water content less than about 1.0%, capric acid less than about 2.0%; caprylic acid (C_8) about 50 to 80%, capric acid (C_{10}) about 20 to 50%, capric acid (C_{12}) less than about 3% and myristic acid (C_{14}) less than about 1.0%, hydrophilic liophilic balance, referred to as HLB, value of about 14; polyoxyethylene sorbitan fatty acid esters, like polysorbate 20,

polysorbate 40, polysorbate 80, more preferably polysorbate 80; polyoxyethylene castor oil derivatives, like cremophor RH 40, cremophore EL, preferably cremophore RH 40.

The preservative, to protect the formulation during storage and use from any microbial growth, particularly in tropical region, is selected from a group consisting of ethanol, benzyl alcohol.

In accordance to the present invention the immunosuppression agent is taken in an amount of about 2 to 10%, preferably in an amount of about 5 to 10%. It is taken in ratio of about 1:0.5, more preferably of about 1:2.5 by weight with respect to hydrophilic agent. The hydrophilic agent is taken alone or in combination. The hydrophilic agent is taken in weight ratio of about 1:1 to 1:6. The preferably used hydrophilic agent is ethanol, which is taken in the ratio of about 1:0.5 to about 1:2.5 with respect to immunosuppression agent. The other preferred hydrophilic agent is diethylene glycol monoethyl ethers. The lipophilic agent, preferably medium chain triglyceride of caprylic and capric acids is taken in the ratio of about 1:0.5, preferably of about 1:2, more preferably of about 1:4 by weight for entrapment of solubilised immunosuppression agent, particularly cyclosporine, more particularly cyclosporine A. The other lipophilic agents used in the present invention include capmul MCM and crodamal GTCC, which are used in the ratio of about 1:0.5 to 1:4 by weight with respect to hydrophilic agent. Still other lipophilic agent of the present invention includes combination of labrafac and labrasol are taken in the ratio of about 1:3, preferably of about 1:3.5, more preferably of about 1:4 by weight. In accordance to the present invention labrasol acts as surfactant.

The surfactants, in accordance to the present invention, include transesterified caprylic and/or capric glyceride, like labrasol, which is taken in the ratio of about 2:1, preferably of about 3:1, more preferably of about 4:1 by weight with respect to lipophilic agent of the present invention. In accordance to one of the preferred embodiments of the present invention the labrasol is used in combination with one or more of other surfactants, like cremophore RH 40 in the ratio of about 1:1, preferably of about 2.5:1 by weight or with polysorbate 80 in the ratio of about 2:1, preferably of about 4.5:1 by weight. In accordance to one of the preferred embodiment of this invention the combination of labrasol, cremophor RH 40, polysorbate 80 is taken in the ratio of about 4:1:1.5 by weight respectively which gives clear translucent microemulsions with bluish tinge and particle size less than 100 nm.

The preservative, in accordance to the present invention, includes benzyl alcohol in the amount of about 0.5 to 1% by weight.

The antioxidant, in accordance to the present invention, includes alpha-tocopherol in the amount of about 0.0008 to 0.0009%.

5 The formulation of the present invention can be prepared by any known method. The preferred method, in accordance to one of the preferred embodiments of this invention comprises of following steps ;-

- a) dissolution of immunosuppression agent in hydrophilic agent,
- b) entrapping of solubilised immunosuppression agent with lipophilic agent,
- 10 c) treatment of oil entrapped solubilised form of drug with one or more of surfactants,
- d) treatment of solubilised drug entrapped with oil and one or more of surfactants with preservative and antioxidant.

In accordance to the preferred method of the present invention the first step involves dissolution of selected amount of immunosuppression agent in selected amount
 15 of hydrophilic agent. The concentration of hydrophilic agent is optimized to such a level in the present invention, that it will keep the immunosuppression agent in solubilized form till the formulation shelf life. The solubilisation step of the presently disclosed method is followed by entrapping with selected amount of presently disclosed lipophilic agent, which acts as carrier during the absorption of the drug, particularly of immunosuppression
 20 agent in the gastrointestinal tract. The third step of the presently disclosed process for manufacture of presently disclosed formulation involves treatment of oil entrapped solubilised form of drug with selected amount of one or more of the surfactants. The fourth step of the presently disclosed process for manufacture of presently disclosed formulation involves treatment of solubilised drug entrapped with oil and one or more of
 25 surfactants with selected amount of the preservative and antioxidant.

In accordance to one of the preferred embodiments of the present invention the formulation is made available in a shell, preferably soft shell, wherein the said shell essentially comprises of gelatin, glycerin, water and one or more of preservatives, like methyl paraben, propyl paraben, and one or more of colorants, like iron oxide black,
 30 titanium dioxide.

In accordance to the preferred embodiment of the present invention, the formulation having presently disclosed composition and prepared in accordance to the preferred method, as described herein above is filled in the shell, preferably in the soft

shell, more preferably in the disintegrating soft gelatin shell, which becomes part of the formulation for oral administration and it can not be separate entity of the medicament taken by the patient.

However, the present invention is not restricted by making availability of the formulation filled in the presently disclosed shell. It is obvious to those who have knowledge of the art that the presently disclosed formulation can also be administered in the form of solution or after filling in any of the known shell, which may be soft or hard shell. It is further obvious to those who have knowledge of the art that the presently disclosed shell can also be used for filling any other formulation including similar formulation.

Therefore, in accordance to one of the preferred embodiments the present invention a disclosure is made of shell essentially comprising of gelatin, glycerin, water and one or more of preservatives, like methyl paraben, propyl paraben, and one or more of colorants, like iron oxide black, titanium dioxide, wherein gelatin is taken in an amount of about 35 to 50% by weight, glycerin is taken in an amount of about 15 to 30% by weight, the preservatives, like methyl paraben, propyl paraben are taken in an amount of about 0.2% by weight, water is taken in an amount of about 30 to 45% by weight, colorants, like iron oxide black, titanium dioxide are taken in an amount of about 0.5%.

It is obvious from the foregoing description that the advantages of the presently disclosed selfemulsifiable formulation for oral administration, as disclosed and described herein above includes increased solubility, transport rate, bioavailability and bioabsorption of the immunosuppression agent; capability of making early bioavailability of the immunosuppression agent, particularly in the upper part of the gastrointestinal tract; capability to meet satisfactorily the clinical requirements; capability to form microemulsions of particle size less than 200 nm, preferably less than 100 nm whether administered orally in the form of microemulsions mixed with fruit juice, milk or any aqueous medium, or administered orally after filling in a soft or hard shell; capability to facilitate the availability of the immunosuppression agent, preferably in the upper part of the gastrointestinal tract in less than 12 minutes, more preferably in less than 10 minutes by rupturing the shell; reduced inter and intra patient bioabsorption variability; capability to be stored in the tropical countries for a longer time; capability to form thermodynamically stable oil in water microemulsions *in-situ*, which are stable for more

than 24 hrs and also having capability to be administered orally after filling in a soft or hard shell, or in the form of solution.

In accordance to the preferred embodiments of the present invention a novel selfemulsifiable formulation having enhanced bioabsorption, bioavailability and immunosuppression activities and comprising of a novel lipophilic system consisting of medium chain triglyceride of caprylic acid and capric acid (labrafac lipophile) and labrasol, wherein labrasol also serves as surfactant, which is combined with other selected surfactants, like cremophore RH 40 and/or polysorbate 80 is disclosed, wherein said formulation also comprises of an immunosuppression agent, hydrophilic agent, antioxidant and preservative, wherein said immunosuppression agent is essentially cyclosporine having immunosuppression activity and said hydrophilic agent is preferably ethanol, said antioxidant is preferably alpha-tocopherol and said preservative is preferably benzyl alcohol, and said formulation is prepared by dissolving immunosuppression agent in hydrophilic agent followed by entrapping of solubilised immunosuppression agent with lipophilic agent and subsequent treatment with one or more of surfactants, and preservative and antioxidant, and is filled in soft-gelatine shell, which is capable of rupturing preferably in less than 10 minutes to deliver the formulation in upper part of gastrointestinal tract, wherein it forms thermodynamically stable oil in water microemulsions *in-situ* to have enhanced bioavailability and bioabsorption of the immunosuppression agent, which can show its enhanced immunosuppression activities thereby.

Experiments

The presently disclosed formulations were prepared in accordance to the preferred method of preparation, as described herein above, and phase diagrams (Figure 1), relative concentrations of various phases, i.e. oil phase, water phase and mixture of surfactants (Figure 2), rupture identification test in dissolution medium by analysing the percent drug content at different time intervals (Figure 3), percent amount of normalised particle size (Figure 4) and mean plasma concentration of the drug (cyclosporine) after administration of the shell (Figure 5) were studied/carried out in case of selected preparations XIII, XIV and/or XV.

It was observed that all formulations were observed to be clear solutions, some formulations were slightly turbid in contact with aqueous media but when subjected to

particle size analysis, passes the microemulsion properties. The formulations were filled in soft gelatin shell of the present invention.

The formulations were prepared having compositions as given in figure 6. For experimental purpose only different combinations of said agents were used. However, the combination of experiments XIII, XIV and XV, particularly of XIV and XV were observed to better and were according to the preferred embodiments of the present invention. These experimental formulations were subjected to microemulsion tests. From these experiments it was observed that presence of labrafac lipophile as lipophilic agent in combination with other selected agents improves the microemulsion quality significantly.

Now referring to accompanying figures, the figure 1 shows the two way plot for cyclosporine microemulsion – phase behaviour. These phases are mixture of surfactants (I), oil phase (II) and water phase (III). Point 1 represents water in oil microemulsion existence, while point 2 represents oil in water microemulsion existence part and point 3 is coarse emulsion part while point 4 is micelle phase. According to this phase diagram, the oil phase (II) contains 10% of cyclosporine-A dissolved in hydrophilic agent and then entrapped in oil. The oil phase (II) concentration increase from 0% along the left-hand margin to 100% as shown by arrow. The concentration of aqueous phase (III) increase from 0% along the right hand margin to 100% as shown by arrow, while the concentration of surfactants mixture (I) increase from 0% at the base line of the plot to 100% as shown by arrow. The relative portion of oil, surfactants and water phases will suitably lie with the area (2), i.e. microemulsion existence field as shown in the figure 1. All the experiments were carried out in the laboratory at a temperature less than 25°C having relative humidity less than 60%.

The figure 2 shows three way plot for cyclosporine microemulsion. This figure represents the relative concentration of oil phase (II), water phase (III) and mixture of surfactants (I). The point A represents the preferred concentration of microemulsion that is oil phase (II), water phase (III) and surfactant phase (I).

The figure 3 represents the comparative dissolution profile of experiments XIII, XIV, XV and standard experiment for which Sandimmun Neoral was taken as standard. The X-axis represents time in minutes required to rupture the shell as USP-specification for cyclosporine shells. The rupture time was identified by content analysis in the dissolution fluid. The Y-axis represents the percentage of cyclosporine dissolved in

dissolution fluid, which was analysed by high performance liquid chromatography (HPLC).

In view of stringent dissolution test specification of cyclosporine capsule USP in USP/NF 24 that each capsule should rupture within 15 minutes, the presently disclosed formulation of immunosuppression agent, particularly cyclosporine was also subjected to dissolution tests as per USP specifications and tested for rupture test and shell stability test. The soft gelatin shells having following compositions were used in four set of experiments for these studies :-

Experiment No. →	A	B	C	D
Ingredient ↓	Composition			
Gelatin	35%	40%	45%	45%
Glycerine	15%	25%	25%	20%
Sorbitol	18.7%	---	---	---
Propyl Paraben	0.04%	0.04%	0.04%	0.04%
Methyl Paraben	0.76%	0.76%	0.76%	0.76%
Colorants	0.5%	0.5%	0.5%	0.5%
Water	30.0%	33.7%	28.7%	33.7%

The soft gelatin shells having above compositions were prepared in accordance to the preferred method of the present invention and were cured at lower humidity and temperature for less than 25°C for sufficient time. The cured shells were subjected to rupture test. The in-vitro dissolution conditions were maintained as follows :-

Apparatus	:	USP Type-II (paddle)
Medium	:	Water (500 ml)
Rotation per minute (RPM)	:	50
Temperature of medium	:	37°C
Time	:	15 mins

As per USP dissolution test of cyclosporine, it mentions the rupture of the shell should be within 15 mins. In the present invention, the efforts were taken not only to comply with the dissolution but also to quantify the rupture time, which gives clear identification of the rupture. The rupture identification tests have been designed and were performed in dissolution medium by analysing the percent drug content at different time intervals, viz. 8, 12 and 15 minutes by HPLC). The percent drug contents for each rupture time interval are given in figure 3, as described herein above. The percent drug contents in case of experiments XIII, XIV, XV and standard (Sandimmun Neoral) were observed to

be 30, 31.8, 35 and 0 respectively at time interval of 8 mins, and 75, 70.86, 75 and 28.73 respectively at time interval of 12 mins, and 90, 86.83, 95 and 91.01 respectively at time interval of 15 mins. This data clearly shows that the shell of the present invention releases higher amount of the drug as compared to the standard.

5 The figure 4 represents percent amount of normalised particle size in experiment XV, the best mode of the present invention. The X-axis represents the particle diameter in nm and Y-axis represents the amount of normalised particle size in percent. It is observed from the figure that the mean particle size is less than 100 nm.

10 The figure 5 represents the mean plasma concentration of cyclosporine after administration of shells of the present invention of experiment XV. The X-axis represents the time in hours and Y-axis represents mean plasma concentration in ng/ml. It is observed from the figure that the mean plasma concentration that is the bioavailability of the drug is more than the standard at the early part of the gastrointestinal tract and having the less variability in the inter and intra patient for the dose response.

15 The presently disclosed formulation (experiment XV) was subjected to bioequivalence study and the results were compared with the standard – Sandimmun Neoral. The bioequivalence study of formulation of experiment XV, best mode of performing the present invention, was carried out on 24 healthy male subjects using 50 mg of sample of this preparation and the results were compared with 50 mg of sample of
20 Sandimmun Neoral. All the subjects were adult, healthy, non-smoking males. The mean (\pm S.E.) age and weight for the subjects were 27.42 ± 0.97 years and 63.63 ± 1.38 kg respectively. Subjects were selected for the participation in the study after providing informed written consent and successfully completing a battery of medically related examinations including medical history, complete physical examination,
25 electrocardiogram and a laboratory profile with hematological, urine and biochemical tests. Subjects were excluded if they had received any drug that are known to induce the drug-metabolising enzymes within three months of study entry. History of hypersensitivity to any drug was ruled out. In a randomized cross over and comparative study designed, 24 subjects received these two preparations on two occasions with a wash out period of two
30 weeks. Subjects reported to the test facility in the evening before drug administration. No food was permitted for at least 10 hrs before the administration of the drug. Next morning after attending to the morning routine, subjects were made to lie to supine. An indwelling teflon needle was introduced in the left fore arm vein and fasting blood sample was

collected. Two shells of either formulations were administered with 240 ml of water. Blood was collected in centrifuge tube containing 0.1 ml of 10% EDTA. Post dose sampling time after drug administration were 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00 10.00, 12.00, 24.00 and 48.00 hrs. Blood samples were centrifuged in cooling centrifuge, maintained at $-20^{\circ}\text{C} \pm 5^{\circ}\text{C}$; with appropriate labels, identifying subject numbers, study day and time of blood collection. Fluid intake was controlled and consistent for the first four hours following drug administration as follows : drug was administered with 240 ml of water, 280 ml of a non-caffeine containing soft drink provided 4.0 hrs post dose. Water was allowed ad libitum there after. Standardised breakfast, lunch and dinner were served to the subjects at 4.0, between 7 to 8 hrs and 14 hrs respectively. Emergence of symptoms, if any were noted by the subjects at the end of the study in the symptom check list formed. The subjects were housed in the laboratory for the entire period. It was randomised comparative study with a two way cross over design. Plasma cyclosporine levels were measured by HPLC method. The drug was extracted from plasma and injected on HPLC system. The chromatography was carried out on C_{18} column using acetonitrile:distilled water in the ratio of 70:30 (v/v) at flow rate of 1.0 ml per min at 80°C . The detection was carried out using a UV-detector. The lowest limit of qualification of the drug from plasma 20 ng/ml.

Administration of standard formulation (Sandimmun Neoral) showed a maximum concentration of cyclosporine 218.2 ± 16.9 ng/ml in plasma (C_{max}) ($\ln C_{\text{max}}$ 5.2979 ± 0.0936) at 2.42 ± 0.16 hrs (T_{max}), while that of test formulation (Experiment XV) showed a maximum concentration of cyclosporine 208.5 ± 12.8 ng/ml (C_{max}) ($\ln C_{\text{max}}$ 5.2912 ± 0.0673) at 2.29 ± 0.11 hrs (T_{max}).

The $\text{AUC}_{(0-t)}$ for standard formulation was 518.35 ± 50.15 ng/ml x hr ($\ln \text{AUC}_{(0-t)}$ 6.1406 ± 0.1010) and for test formulation, it was 518.71 ± 46.97 ng/ml x hr ($\ln \text{AUC}_{(0-t)}$ 6.1238 ± 0.1163).

The $\text{AUC}_{(0-\infty)}$ for standard formulation was 611.64 ± 54.55 ng/ml x hr ($\ln \text{AUC}_{(0-\infty)}$ 6.3262 ± 0.0897) and for test formulation, it was 597.27 ± 50.13 ng/ml x hr ($\ln \text{AUC}_{(0-\infty)}$ 6.2847 ± 0.1062).

The elimination rate constants for standard and test formulations were 0.140 ± 0.023 hr^{-1} and 0.168 ± 0.028 hr^{-1} and elimination half-lives were 7.98 ± 0.97 hrs and 7.34 ± 1.44 hrs respectively.

In this study, with both the formulations, standard and experiment XV, cyclosporine was detected in plasma in few subjects at 0.50 hrs after ingestion of formulation. Cyclosporine was detected up to 8 hrs in some of the subjects post-dose with both the formulations. C_{max} values, time at which they were achieved T_{max} were comparable with both the formulations, so also were $AUC_{(0-t)}$, $AUC_{(0-\infty)}$, K_{el} and $T_{1/2}$. When ANOVA was applied with the subjects, period and treatment as variables no significant variation was observed for T_{max} , whereas subject parameter was found significant for C_{max} , $\ln C_{max}$, $AUC_{(0-t)}$, $\ln AUC_{(0-t)}$, $AUC_{(0-\infty)}$ and $\ln AUC_{(0-\infty)}$.

The 90% confidence interval for cyclosporine for the C_{max} , $AUC_{(0-t)}$ and $AUC_{(0-\infty)}$ values were 87.26% to 104.34%, 84.10% to 117.23% and 81.76% to 114.60% respectively. For the log-transformed data they were 90.54% to 109.69%, 82.24% to 118.00% and 80.21% to 115.57% respectively. The ratio of the least squares means of the C_{max} , $AUC_{(0-t)}$ and $AUC_{(0-\infty)}$ of the test/standard were 95.56%, 100.07% and 97.65% respectively. For the log-transformed data the ratios were 99.87%, 99.73% and 99.34% respectively.

The power of test for cyclosporine for the C_{max} , $AUC_{(0-t)}$ and $AUC_{(0-\infty)}$ value was 97.44% and for log-transformed data it was 91.15%. The inter-subject variability for cyclosporine for C_{max} , $AUC_{(0-t)}$ and $AUC_{(0-\infty)}$ values were 17.54%, 33.18% and 33.31% respectively. For log-transformed data the values were 19.46%, 37.51% and 37.98% respectively. When $AUC_{(0-t)}$ of both the formulations were compared, experiment XV and Sandimmun Neoral showed bioavailability of 100.07%.

The bioequivalence data of both the formulations – standard and experiment XV using 50 mg shells is given below. The mean (ng/ml), S.D., S.E. and COV (%) were measured at time intervals of 0.00, 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 5.00, 6.00, 8.00 10.00, 12.00, 24.00 and 48.00 hrs.

Time in hrs	Sandimmun Neoral				Experiment XV			
	Mean (ng/ml)	S.D.	S.E.	COV (%)	Mean (ng/ml)	S.D.	S.E.	COV (%)
0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
0.50	19.1	56.4	11.5	295.81	22.8	42.0	8.6	184.41
1.00	66.7	95.3	19.5	142.81	71.8	51.4	10.5	71.58
1.50	137.2	92.1	18.8	67.13	121.0	62.1	12.7	51.34
2.00	150.6	77.5	15.8	51.50	160.6	74.2	15.1	46.17

2.50	163.4	78.4	16.0	48.01	164.9	62.5	12.8	37.89
3.00	159.8	92.2	18.8	57.72	157.2	72.6	14.8	46.17
3.50	114.7	57.6	11.8	50.25	109.8	64.7	13.2	58.96
4.00	75.3	62.7	12.8	83.27	73.2	58.1	11.9	79.41
5.00	37.9	39.6	8.1	104.54	42.3	43.9	9.0	103.96
6.00	21.4	27.9	5.7	130.08	19.0	25.6	5.2	134.78
8.00	4.6	10.7	2.2	232.42	7.0	14.3	2.9	203.34
10.00	1.2	5.7	1.2	489.71	0.0	0.0	0.0	0.0
12.00	1.1	5.5	1.1	490.04	0.0	0.0	0.0	0.0
24	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
48	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AUC _(0-t)	518.35	245.75	50.16	47.41	518.72	230.14	46.98	44.37
AUC _(0-∞)	611.64	267.32	54.57	43.70	597.27	245.61	50.14	41.12

The mean and \pm SEM of both the preparations for C_{\max} (ng/ml), $\ln C_{\max}$, T_{\max} , $AUC_{(0-t)}$ (ng/ml * hr), $\ln AUC_{(0-t)}$, $AUC_{(0-\infty)}$ (ng/ml * hr), $\ln AUC_{(0-\infty)}$, $T_{1/2}$ hr and K_{el} / hr are given below :

5

Preparation→	Sandimmun Neoral		Experiment XV	
Parameter ↓	Mean	\pm SEM	Mean	\pm SEM
C_{\max}	218.2	16.9	208.5	12.8
$\ln C_{\max}$	5.2979	0.0936	5.2912	0.0673
T_{\max}	2.42	0.16	2.29	0.11
$AUC_{(0-t)}$	518.35	50.15	518.71	46.97
$\ln AUC_{(0-t)}$	6.1406	0.1010	6.1238	0.1163
$AUC_{(0-\infty)}$	611.64	54.55	597.27	50.13
$\ln AUC_{(0-\infty)}$	6.3262	0.0897	6.2847	0.1062
$T_{1/2}$	7.98	0.97	7.34	1.44
K_{el}	0.140	0.023	0.168	0.028

The above bioequivalence data shows that the trial of composition of formulation of experiment XV has less percentage of Coefficient of Variation (COV) and standard error (SE) than the standard formulation. From this data, it can be concluded that the presently disclosed formulation shows significantly less variability in inter and intra patient dose response than the standard formulation, which is a unique characteristic

10

required for the formulation, particularly for the cyclosporine formulation microemulsions. From the above bioequivalence data, one another advantage of the presently disclosed formulation which is apparent, is that the soft gelatin shell having very low rupture time, that is, about 8 mins, will give fast release of the drug out of the
5 formulation for the immediate bioavailability of the drug, that is, of the immunosuppression agent, that is, of the cyclosporine, i.e. 22.8 ng/ml in 30 mins as against standard formulation i.e. 19.1 ng/ml.

Claims

1. A selfemulsifiable formulation for oral administration, wherein said formulation essentially comprises of immunosuppression agent, hydrophilic agent, lipophilic agent, one or more of surfactants, antioxidant and preservative, wherein
5 said immunosuppression agent is preferably lactam macrolide having immunosuppression activity;
said hydrophilic agent is selected from a group consisting of pharmaceutically acceptable C_{1-5} alkyl, tetrahydrofuryl diether, tetrahydrofuryl partial ether, low molecular weight monooxy-alkane-diol, low molecular weight polyoxy-alkane-
10 diol, 1,2-propyleneglycol, ethanol;
said lipophilic agent is selected from a group consisting of medium chain monoglycerides, medium chain diglycerides, mixed esters of saturated fatty acids, like caprylic and/or capric acids, medium chain triglycerides of caprylic and/or capric acids;
15 said one or more of surfactants are selected from a group consisting of hydrogenated vegetable oils, polyoxyethylene sorbitan fatty acids, transesterified caprylic and/or capric glycerides;
said antioxidant is selected from a group consisting of alpha-tocopherol, ascorbyl palmitate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gallate; and
20 said preservative is selected from a group consisting of ethanol, benzyl alcohol.
2. A selfemulsifiable formulation, as claimed in claim 1, wherein preferred said lipophilic agent is medium chain triglyceride of caprylic acid and capric acid.
3. A selfemulsifiable formulation, as claimed in claims 1 and 2, wherein said medium chain triglyceride of caprylic acid and capric acid has specific gravity of about 0.93
25 to 0.96, refractive index of about 1.44 to 1.46, acid value less than about 0.2, saponification value of about 310 to 360 and iodine value less than about 1 and water content less than about 0.5.
4. A selfemulsifiable formulation, as claimed in claim 1, wherein said immunosuppression agent is particularly cyclosporine, more particularly
30 cyclosporine-A having immunosuppression activity.
5. A selfemulsifiable formulation, as claimed in claim 1, wherein said hydrophilic agent is additionally selected from a group consisting of pharmaceutically acceptable lower (C_{1-4}) alkanols, like ethanol; alkylene glycol monoalkyl ethers,

like diethylene glycol monoethyl ethers, transcitol, glycofural (known as tetrahydrofuryl) alcohol polyethylene glycol ether. The preferred hydrophilic agent is lower alkanol, more preferable hydrophilic agent is ethanol.

6. A selfemulsifiable formulation, as claimed in claim 1, wherein said one or more of
5 surfactants are additionally selected from a group consisting of saturated polyglycolysed C₈ to C₁₀ glycerides, like transesterified caprylic and/or capric glycerides, particularly PEG-8 caprylic and/or capric acid glyceride; polyoxyethylene sorbitan fatty acid esters, like polysorbate 20, polysorbate 40, polysorbate 80, more preferably polysorbate 80; polyoxyethylene castor oil
10 derivatives, like cremophor RH 40, cremophore EL, preferably cremophore RH 40.
7. A selfemulsifiable formulation, as claimed in claims 1 and 6, wherein said caprylic and capric acid glyceride (labrasol) exhibits specific gravity of about 0.930 to 0.960, refractive index of about 1.44 to 1.452, acid value less than about 0.2, saponification value of about 85 to 105, peroxide value less than about 6.0. free
15 glycerol content less than about 5.0%, ethylene oxide content of about 1.0 ppm, water content less than about 1.0%, capric acid less than about 2.0%, caprylic acid (C₈) about 50 to 80%, capric acid (C₁₀) about 20 to 50%, capric acid (C₁₂) less than about 3% and myristic acid (C₁₄) less than about 1.0%, hydrophilic liophilic balance value of about 14.
- 20 8. A selfemulsifiable formulation, as claimed in claim 1, wherein said immunosuppression agent is taken in an amount of about 2 to 10%, preferably in an amount of about 5 to 10%.
9. A selfemulsifiable formulation, as claimed in claim 1, wherein said immunosuppression agent and hydrophilic agent are taken in ratio of about 1:0.5,
25 more preferably of about 1:2.5 by weight.
10. A selfemulsifiable formulation, as claimed in claim 1, wherein said lipophilic agent is taken in the ratio of about 1:0.5, preferably of about 1:2, more preferably of about 1:4 by weight.
11. A selfemulsifiable formulation, as claimed in claim 1, wherein said one or more of
30 surfactants are taken in the ratio of about 2:1, preferably of about 3:1, more preferably of about 4:1 by weight with respect to lipophilic agent.
12. A selfemulsifiable formulation, as claimed in claim 1, wherein said surfactant is combination of labrasol and cremophore RH 40 or labrasol and polysorbate 80 and

are taken in the ratio of about 1:1, preferably of about 2.5:1, more preferably of about 4.5:1 by weight.

13. A selfemulsifiable formulation, as claimed in claim 1, wherein said surfactant is combination of labrasol, cremophor RH 40, polysorbate 80 and is taken in the ratio of about 4:1:1.5 by weight respectively.
14. A selfemulsifiable formulation, as claimed in claim 1, wherein said preservative is preferably benzyl alcohol and is taken in the amount of about 0.5 to 1% by weight.
15. A selfemulsifiable formulation, as claimed in claim 1, wherein said antioxidant is preferably alpha-tocopherol and is taken in the amount of about 0.0008 to 0.0009%.
16. A selfemulsifiable formulation, as claimed in claim 1, wherein said formulation forms microemulsions of particle size less than 200 nm, preferably less than 100 nm on contact with gastric juice or aqueous medium.
17. A selfemulsifiable formulation, as claimed and described herein above.
18. A method of preparation of selfemulsifiable formulation according to claims 1 to 17, wherein said method comprises of following steps :-
 - a) dissolution of immunosuppression agent in hydrophilic agent,
 - b) entrapping of solubilised immunosuppression agent with lipophilic agent,
 - c) treatment of oil entrapped solubilised form of drug with one or more of surfactants,
 - d) treatment of solubilised drug entrapped with oil and one or more of surfactants with preservative and antioxidant.
19. A method of preparation of selfemulsifiable formulation as claimed in claim 18 and described herein above.
20. A selfemulsifiable formulation, as claimed in claims 1 to 17, wherein said formulation is made available in a soft shell, wherein the said shell essentially comprises of gelatin, glycerin, water and one or more of preservatives, like methyl paraben, propyl paraben, and one or more of colorants, like iron oxide black, titanium dioxide.
21. A shell according to claim 20, wherein gelatin is in taken in an amount of about 35 to 50% by weight.
22. A shell according to claim 20, wherein, glycerin is taken in an amount of about 15 to 30% by weight.

23. A shell according to claim 20, wherein, the preservatives are taken in an amount of about 0.2% by weight.
24. A shell according to claim 20, wherein, water is taken in an amount of about 30 to 45% by weight.
- 5 25. A shell according to claim 20, wherein, colorant is taken in an amount of about 0.5% by weight.
26. A shell for formulation, as claimed in claims 20 to 25 and described herein above.
27. A selfemulsifiable formulation, as claimed herein above, wherein said formulation is administered in soft shell or hard shell or in solution form.
- 10 28. A selfemulsifiable formulation, as claimed herein above, wherein said formulation is administered for immunosuppression therapy.

AMENDED CLAIMS

[received by the International Bureau on 18 January 2002 (18.01.02);
original claims 2, 3, 4, 5, 9, 11, 13-17 and 23-25 amended; claims 26-28 cancelled;
remaining claims unchanged (4 pages)]

1. A selfemulsifiable formulation for oral administration, wherein said formulation essentially comprises of immunosuppression agent, hydrophilic agent, lipophilic agent, one or more of surfactants, antioxidant and preservative, wherein
 5 said immunosuppression agent is preferably lactam macrolide having immunosuppression activity;
 said hydrophilic agent is selected from a group consisting of pharmaceutically acceptable lower (C₁₋₄) alkanols; alkylene glycol monoalkyl ethers; low molecular weight monooxy-alkane-diol; low molecular weight polyoxy-alkane-diol; 1,2-
 10 propyleneglycol; particularly lower (C₁₋₄) alkanols; more particularly ethanol;
 said lipophilic agent is selected from a group consisting of medium chain monoglycerides; medium chain diglycerides; mixed esters of saturated fatty acids; medium chain triglycerides of caprylic and/or capric acids; particularly medium chain triglycerides of caprylic and capric acids;
 15 said one or more of surfactants are selected from a group consisting of saturated polyglycolysed C₈ to C₁₀ glycerides, particularly transesterified caprylic and capric glycerides; polyoxyethylene sorbitan fatty acid esters, particularly polysorbate 80; polyoxyethylene castor oil derivatives, particularly cremophor RH 40;
 said antioxidant is selected from a group consisting of alpha-tocopherol, ascorbyl
 20 palmitate, butyl hydroxy anisole, butyl hydroxy toluene, propyl gallate; and
 said preservative is selected from a group consisting of ethanol, benzyl alcohol.
2. A selfemulsifiable formulation, as claimed in claim 1, wherein said medium chain triglyceride of caprylic acid and capric acid has specific gravity of about 0.93 to 0.96, refractive index of about 1.44 to 1.46, acid value less than about 0.2,
 25 saponification value of about 310 to 360 and iodine value less than about 1 and water content less than about 0.5.
3. A selfemulsifiable formulation, as claimed in claim 1, wherein said immunosuppression agent is particularly cyclosporine, more particularly cyclosporine-A having immunosuppression activity.
- 30 4. A selfemulsifiable formulation, as claimed in claim 1, wherein said transesterified caprylic and capric acid glyceride (labrasol) exhibits specific gravity of about 0.930 to 0.960, refractive index of about 1.44 to 1.452, acid value less than about 0.2, saponification value of about 85 to 105, peroxide value less than about 6.0,

free glycerol content less than about 5.0%, ethylene oxide content of about 1.0 ppm, water content less than about 1.0%, capric acid less than about 2.0%, caprylic acid (C₈) about 50 to 80%, capric acid (C₁₀) about 20 to 50%, capric acid (C₁₂) less than about 3% and myristic acid (C₁₄) less than about 1.0%, hydrophilic liophilic balance value of about 14.

- 5 5. A selfemulsifiable formulation, as claimed in claim 1, wherein said immunosuppression agent is taken in an amount of about 2 to 10%, preferably in an amount of about 5 to 10%.
- 10 6. A selfemulsifiable formulation, as claimed in claim 1, wherein said immunosuppression agent and hydrophilic agent are taken in ratio of about 1:0.5 to 1:2.5, more preferably of about 1:1.25 by weight.
- 15 7. A selfemulsifiable formulation, as claimed in claim 1, wherein said lipophilic agent is present in the system in the ratio of immunosuppression agent to lipophilic agent of about 1:0.5, preferably of about 1:1.5 or 1:1.7, more preferably of about 1:4 by weight.
8. A selfemulsifiable formulation, as claimed in claim 1, wherein said one or more of surfactants are taken in the ratio of about 2:1, preferably of about 3:1, more preferably of about 6:1 by weight with respect to lipophilic agent.
- 20 9. A selfemulsifiable formulation, as claimed in claim 1, wherein said surfactant is combination of labrasol and cremophore RH 40 or labrasol and polysorbate 80 and are taken in the ratio of about 1:1, preferably of about 2.5:1, more preferably of about 4.5:1 by weight.
- 25 10. A selfemulsifiable formulation, as claimed in claim 1, wherein said surfactant is combination of labrasol, cremophor RH 40, polysorbate 80 and are taken in the ratio of about 4:1:1.5, more preferably in the ratio of about 2.5:1:0.6 by weight respectively.
11. A selfemulsifiable formulation, as claimed in claim 1, wherein said preservative is preferably benzyl alcohol and is taken in the amount of about 0.5 to 1% by weight.
- 30 12. A selfemulsifiable formulation, as claimed in claim 1, wherein said antioxidant is preferably alpha-tocopherol and is taken in the amount of about 0.00007 to 0.00009%.

13. A selfemulsifiable formulation, as claimed in claim 1, wherein said formulation forms microemulsions of particle size less than 200 nm, preferably less than 100 nm on contact with gastric juice or aqueous medium.
14. A selfemulsifiable formulation, as claimed and described herein above.
- 5 15. A method of preparation of selfemulsifiable formulation according to claims 1 to 14, wherein said method comprises of following steps :-
 - a) dissolution of immunosuppression agent in hydrophilic agent,
 - b) entrapping of solubilised immunosuppression agent with lipophilic agent,
 - c) treatment of oil entrapped solubilised form of drug with one or more of
 - 10 surfactants,
 - d) treatment of solubilised drug entrapped with oil and one or more of surfactants with preservative and antioxidant.
16. A method of preparation of selfemulsifiable formulation as claimed in claim 15 and described herein above.
- 15 17. A selfemulsifiable formulation, as claimed in claims 1 to 14, wherein said formulation is made available in a soft shell, wherein the said shell essentially comprises of gelatin, glycerin, water and one or more of preservatives, like methyl paraben, propyl paraben, and one or more of colorants, like iron oxide black, titanium dioxide.
- 20 18. A selfemulsifiable formulation, as claimed in claims 1 to 17, in a soft shell, as defined in claim 17, wherein gelatin is taken in an amount of about 35 to 50% by weight.
19. A selfemulsifiable formulation, as claimed in claims 1 to 17, in a soft shell, as defined in claim 17, wherein glycerin is taken in an amount of about 15 to 30% by
- 25 weight.
20. A selfemulsifiable formulation, as claimed in claims 1 to 17, in a soft shell, as defined in claim 17, wherein preservatives are taken in an amount of about 0.2%, more preferably of about 0.8% by weight.
21. A selfemulsifiable formulation, as claimed in claims 1 to 17, in a soft shell, as
- 30 defined in claim 17, wherein water is taken in an amount of about 30 to 45% by weight.


22. A selfemulsifiable formulation, as claimed in claims 1 to 17, in a soft shell, as defined in claim 17, wherein colorant is taken in an amount of about 0.5% by weight.
23. A shell for formulation, as defined and claimed in claims 17 to 22 and described
5 herein above.
24. A selfemulsifiable formulation, as claimed herein above, wherein said formulation is administered in soft shell or hard shell or in solution form.
25. A selfemulsifiable formulation, as claimed herein above, wherein said formulation is administered for immunosuppression therapy.
- 10

Statement under Article 19(1)

Originally International / PCT Patent Application [No. PCT/IN 00/00091] had 28 claims and now, after amendments by way of merging some claims, there are 25 claims. Original claims 3, 4, 7, 8, 12, 14, 16-20 and 26-28 are unchanged and now appear as claims 2, 3, 4, 5, 9, 11, 13-17 and 23-25 respectively in the amended sheets. Original claims 2, 5 and 6 have been merged in claim 1. Original claims 9, 10, 11, 13 and 15 have been replaced by amended claims 6, 7, 8, 10 and 12 respectively. Original claims 21-25 have been amended to meet the requirement of unity of invention and appear as amended claims 18-22. No new claim has been added. The amended claims do not go beyond the scope of the originally filed patent application.

To have the consistency between amended claims and the description, pages 8-10 of the description have been amended.

Drawing sheet 6/6 has been amended to correct the typographical error in row 1 of column 1.

**FIGURE 1**




FIGURE 2

FIGURE 3






FIGURE 4



BEST AVAILABLE COPY
5 ERUGIF

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IN 00/00091

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/13 A61K9/107 A61K9/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 024 978 A (RICHTER FRIEDRICH ET AL) 15 February 2000 (2000-02-15) column 7, line 15 -column 10, line 29 column 11, line 8 -column 11, line 33 examples 1.1-1.10	1-6,8,9, 11,16, 27,28
X	US 5 589 455 A (WOO JONG S) 31 December 1996 (1996-12-31) column 4, line 65 -column 6, line 29 examples 1-7 -/-	1-6,8,9, 11,16, 27,28

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

17 September 2001

Date of mailing of the international search report

27.09.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Borst, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IN 00/00091

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 48410 A (CIBA GEIGY AG ;WOO JONG SOO (KR)) 24 December 1997 (1997-12-24)	1,4,6,8, 9,11,16, 21-25, 27,28
X	examples 1-6	1,4,6,8, 9,11,16, 27,28
X	example 6.1.	21-25
X	US 5 985 321 A (BROX WERNER ET AL) 16 November 1999 (1999-11-16)	1,4-6,8, 9,16,27, 28
	example 4	
X	US 5 858 401 A (BHALANI VINAYAK T ET AL) 12 January 1999 (1999-01-12)	1,4,6,7, 16,27,28
	example 2	
A	US 4 388 307 A (CAVANAK THOMAS) 14 June 1983 (1983-06-14)	3
	table I	
X	EP 0 982 035 A (PANACEA BIOTECH LTD) 1 March 2000 (2000-03-01)	21-25
	example 11	
X	FR 2 705 568 A (CARILENE LABORATOIRES) 2 December 1994 (1994-12-02)	21-25
	example 1	
X	US 2 870 062 A (BRADLEY CLAYTON W ET AL) 20 January 1959 (1959-01-20)	21-25
	examples 1-3	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IN 00/00091

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 10, 17, 19, 26
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

As a result of the prior review under R. 40.2(e) PCT,
no additional fees are to be refunded.

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 10,17,19,26

Present dependent claim 10, lacking a point of reference for the ratio of lipophilic agent, as well as present dependent claims 17, 19 and 26, defining the subject-matter by reference to what was "described herein above", are not clear (Article 6 PCT).

The wording used therein leads to severe doubts concerning the extent of the protection afforded by the claims so that a meaningful search is not possible.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-9,11-16,18,20,27,28

A self-emulsifiable formulation comprising the immunosuppression agent, a particular hydrophilic phase, a particular lipophilic phase and one or more of a particular surfactant, antioxidant and preservative

2. Claims: 21-25

A shell comprising gelatin, glycerine, water, one or more preservatives and one or more colorants

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IN 00/00091

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6024978	A	15-02-2000	US 5866159 A	02-02-1999
			US 5741512 A	21-04-1998
			US 5342625 A	30-08-1994
			AT 403435 B	25-02-1998
			AT 214289 A	15-07-1997
			AU 627220 B	20-08-1992
			AU 4140089 A	22-03-1990
			BE 1003105 A	26-11-1991
			BG 60525 B	28-07-1995
			CA 1332150 A	27-09-1994
			CH 679118 A	31-12-1991
			CY 1711 A	06-05-1994
			DE 3930928 A	22-03-1990
			DK 171433 B	28-10-1996
			ES 2020738 A	16-09-1991
			FI 894342 A,B,	17-03-1990
			FR 2636534 A	23-03-1990
			GB 2222770 A,B	21-03-1990
			GR 89100583 A,B	31-10-1990
			HK 86593 A	27-08-1993
			HU 9500318 A	30-10-1995
			IE 60764 B	10-08-1994
			IL 91642 A	12-04-1994
			IT 1232243 B	28-01-1992
			JP 1996397 C	08-12-1995
			JP 2121929 A	09-05-1990
			JP 7025690 B	22-03-1995
			KR 148748 B	17-08-1998
			KR 235524 B	15-12-1999
			KR 256007 B	01-05-2000
			KR 267149 B	15-09-2000
			LU 87586 A	07-05-1991
			LV 5749 A	20-12-1996
			NL 8902315 A	17-04-1990
			NO 180362 B	30-12-1996
			NZ 230660 A	25-06-1992
			PT 91731 A,B	30-03-1990
			SE 514303 C	05-02-2001
			SE 8903042 A	11-05-1990
			SG 50793 G	25-06-1993
			US 5962017 A	05-10-1999
			US 6007840 A	28-12-1999
			US 5916589 A	29-06-1999
			US 5962014 A	05-10-1999
			ZA 8907066 A	29-05-1991
US 5589455	A	31-12-1996	KR 167613 B	15-01-1999
WO 9748410	A	24-12-1997	KR 183449 B	01-05-1999
			AU 719251 B	04-05-2000
			AU 3341197 A	07-01-1998
			AU 5948698 A	28-05-1998
			BR 9706804 A	03-11-1999
			CA 2226091 A,C	24-12-1997
			CA 2240705 A	24-12-1997
			CZ 9800834 A	15-07-1998
			CZ 9800835 A	15-07-1998
			EP 0813876 A	29-12-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IN 00/00091

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9748410 A		EP 0869810 A	14-10-1998
		HU 9801109 A	30-08-1999
		JP 2923503 B	26-07-1999
		JP 11100326 A	13-04-1999
		JP 2855135 B	10-02-1999
		JP 10007550 A	13-01-1998
		JP 2000505480 T	09-05-2000
		NO 981200 A	17-03-1998
		NO 982382 A	26-05-1998
		PL 325832 A	04-01-1999
		SI 9720010 A	31-10-1998
		SI 9720011 A	31-10-1998
		SK 37198 A	07-10-1998
		SK 37298 A	07-10-1998
		TR 9800525 T	22-02-1999
		TR 9800526 T	22-02-1999
		US 5958876 A	28-09-1999
		ZA 9705448 A	19-03-1999
		AU 6729398 A	12-10-1998
		BR 9808324 A	16-05-2000
		CN 1250378 T	12-04-2000
		CZ 9903243 A	15-12-1999
		DE 19882184 T	10-02-2000
		WO 9841225 A	24-09-1998
		EP 0969857 A	12-01-2000
		GB 2337703 A	01-12-1999
		HU 0001515 A	28-09-2000
		JP 2000514831 T	07-11-2000
		NO 994436 A	13-09-1999
		PL 335729 A	08-05-2000
		SK 123299 A	14-02-2000
		TR 9902229 T	21-12-1999
		ZA 9802117 A	14-09-1998
US 5985321 A	16-11-1999	AT 198041 T	15-12-2000
		AU 690571 B	30-04-1998
		AU 7423794 A	13-04-1995
		AU 7511298 A	01-10-1998
		CA 2132933 A	29-03-1995
		CN 1108930 A	27-09-1995
		CZ 9402360 A	12-04-1995
		DE 69426408 D	18-01-2001
		DE 69426408 T	12-07-2001
		DK 649651 T	26-02-2001
		EP 1029538 A	23-08-2000
		EP 1033128 A	06-09-2000
		EP 0649651 A	26-04-1995
		ES 2152281 T	01-02-2001
		FI 944452 A	29-03-1995
		FR 2710532 A	07-04-1995
		GB 2282586 A,B	12-04-1995
		GB 2317155 A,B	18-03-1998
		HU 70417 A	30-10-1995
		IL 111067 A	31-12-1999
		IT RM940613 A,B	28-03-1995
		JP 3071642 B	31-07-2000
		JP 7149625 A	13-06-1995
		KR 200174 B	15-06-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IN 00/00091

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5985321 A		KR 202331 B	15-06-1999
		NO 943563 A	29-03-1995
		NZ 264536 A	25-09-1996
		PL 305188 A	03-04-1995
		PT 649651 T	30-03-2001
		RU 2140783 C	10-11-1999
		SG 46531 A	20-02-1998
		SI 649651 T	28-02-2001
		SK 115794 A	10-05-1995
		ZA 9407567 A	28-06-1996
US 5858401 A	12-01-1999	NONE	
US 4388307 A	14-06-1983	CH 636013 A	13-05-1983
		AR 223667 A	15-09-1981
		AT 375828 B	10-09-1984
		AT 163779 A	15-02-1984
		AU 528714 B	12-05-1983
		AU 4486279 A	13-09-1979
		BE 874628 A	05-09-1979
		CA 1139667 A	18-01-1983
		CY 1285 A	05-07-1985
		DD 142149 A	11-06-1980
		DE 2907460 A	13-09-1979
		DK 86079 A,B,	08-09-1979
		ES 478295 A	16-05-1979
		FI 790640 A,B,	08-09-1979
		FR 2419072 A	05-10-1979
		GB 2015339 A,B	12-09-1979
		HK 48585 A	28-06-1985
		HU 182920 B	28-03-1984
		IE 48016 B	05-09-1984
		IL 56790 A	31-01-1982
		IT 1115038 B	03-02-1986
		JP 1404998 C	09-10-1987
		JP 54132223 A	15-10-1979
		JP 62007891 B	19-02-1987
		KE 3516 A	19-04-1985
		MY 13485 A	31-12-1985
		NL 7901703 A,C	11-09-1979
		NO 790661 A,B,	10-09-1979
		NZ 189819 A	31-05-1984
		PH 15159 A	24-08-1982
		PT 69309 A	01-04-1979
		SE 445174 B	09-06-1986
		SE 7901683 A	08-09-1979
		SG 14785 G	16-08-1985
		ZA 7901056 A	29-10-1980
EP 0982035 A	01-03-2000	EP 0985412 A	15-03-2000
FR 2705568 A	02-12-1994	NONE	
US 2870062 A	20-01-1959	NONE	